{"id":295,"date":"2022-05-23T12:02:05","date_gmt":"2022-05-23T10:02:05","guid":{"rendered":"\/blog\/?page_id=295"},"modified":"2025-01-02T17:16:01","modified_gmt":"2025-01-02T16:16:01","slug":"golimumab-simponi","status":"publish","type":"page","link":"\/blog\/traitements\/golimumab-simponi\/","title":{"rendered":"Golimumab (Simponi) 2017-2019"},"content":{"rendered":"<div class=\"wp-block-image\">\n<figure class=\"alignleft size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"685\" src=\"\/blog\/wp-content\/uploads\/2022\/05\/Simponi-Ire-Pack-Shot-1-1024x685.jpg\" alt=\"\" class=\"wp-image-297\" style=\"width:507px;height:339px\" srcset=\"\/blog\/wp-content\/uploads\/2022\/05\/Simponi-Ire-Pack-Shot-1-1024x685.jpg 1024w, \/blog\/wp-content\/uploads\/2022\/05\/Simponi-Ire-Pack-Shot-1-300x201.jpg 300w, \/blog\/wp-content\/uploads\/2022\/05\/Simponi-Ire-Pack-Shot-1-768x514.jpg 768w, \/blog\/wp-content\/uploads\/2022\/05\/Simponi-Ire-Pack-Shot-1-1536x1028.jpg 1536w, \/blog\/wp-content\/uploads\/2022\/05\/Simponi-Ire-Pack-Shot-1-2048x1371.jpg 2048w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>\n\n\n<p>Le golimumab est un anticorps monoclonal humain qui forme des complexes stables \u00e0 forte affinit\u00e9 avec les deux formes bioactives transmembranaire et soluble du TNF-alpha humain, ce qui emp\u00eache la liaison du TNF-alpha \u00e0 ses r\u00e9cepteurs.<br>Il a \u00e9t\u00e9 montr\u00e9 que la liaison du TNF humain au golimumab neutralisait l&rsquo;expression \u00e0 la surface des cellules, induite par le TNF-alpha, des mol\u00e9cules d&rsquo;adh\u00e9sion s\u00e9lectine&nbsp;E, des mol\u00e9cules d&rsquo;adh\u00e9rence des cellules vasculaires-1 (VCAM-1) et des mol\u00e9cules d&rsquo;adh\u00e9sion intercellulaire-1 (ICAM-1) par les cellules endoth\u00e9liales humaines.<br>In vitro, la s\u00e9cr\u00e9tion induite par le TNF d&rsquo;interleukine (IL-6), IL-8 et du facteur de croissance GM-CSF (granulocyte-macrophage colony stimulating factor) par les cellules endoth\u00e9liales humaines \u00e9tait \u00e9galement inhib\u00e9e par le golimumab.<\/p>\n\n\n\n<p><strong><u>Indications th\u00e9rapeutiques:<\/u><\/strong><br><strong>Polyarthrites rhumato\u00efdes<br>Rectocolites h\u00e9morragiques<br>Rhumatismes psoriasiques<br>Spondylarthrites ankylosantes<\/strong><\/p>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-large is-resized\"><img loading=\"lazy\" decoding=\"async\" width=\"1024\" height=\"768\" src=\"\/blog\/wp-content\/uploads\/2025\/01\/Simponi_golimumab_50_mg_prefilled_syringe-1024x768.jpg\" alt=\"\" class=\"wp-image-403\" style=\"width:504px;height:auto\" srcset=\"\/blog\/wp-content\/uploads\/2025\/01\/Simponi_golimumab_50_mg_prefilled_syringe-1024x768.jpg 1024w, \/blog\/wp-content\/uploads\/2025\/01\/Simponi_golimumab_50_mg_prefilled_syringe-300x225.jpg 300w, \/blog\/wp-content\/uploads\/2025\/01\/Simponi_golimumab_50_mg_prefilled_syringe-768x576.jpg 768w, \/blog\/wp-content\/uploads\/2025\/01\/Simponi_golimumab_50_mg_prefilled_syringe-1536x1152.jpg 1536w, \/blog\/wp-content\/uploads\/2025\/01\/Simponi_golimumab_50_mg_prefilled_syringe-2048x1536.jpg 2048w, \/blog\/wp-content\/uploads\/2025\/01\/Simponi_golimumab_50_mg_prefilled_syringe-800x600.jpg 800w\" sizes=\"auto, (max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>Le golimumab est un anticorps monoclonal humain qui forme des complexes stables \u00e0 forte affinit\u00e9 avec les deux formes bioactives transmembranaire et soluble du TNF-alpha<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":278,"menu_order":3,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-295","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"\/blog\/wp-json\/wp\/v2\/pages\/295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"\/blog\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"\/blog\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"\/blog\/wp-json\/wp\/v2\/comments?post=295"}],"version-history":[{"count":3,"href":"\/blog\/wp-json\/wp\/v2\/pages\/295\/revisions"}],"predecessor-version":[{"id":404,"href":"\/blog\/wp-json\/wp\/v2\/pages\/295\/revisions\/404"}],"up":[{"embeddable":true,"href":"\/blog\/wp-json\/wp\/v2\/pages\/278"}],"wp:attachment":[{"href":"\/blog\/wp-json\/wp\/v2\/media?parent=295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}